References
- Effective strategies to advance access to biologic therapies for non-communicable diseases: a biosimilar medicines access Policy Blueprint. IGBA. Oct 2021. Available from: https://www.globalbiosimilarsweek.org/2021/doc/A-Biosimilar-medicines-Access-Policy-Blueprint-IGBA.pdf
- Biosimilar drugs promise to slash health-care costs in rich countries. The Economist. cited Nov 10 2018. Available from: https://www.economist.com/business/2018/11/10/biosimilar-drugs-promise-to-slash-health-care-costs-in-rich-countries
- Troein P, Newton M, Stoddart K, et al. The impact of biosimilar competition in Europe. IQVIA. Dec 2022. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2022.pdf
- Expanding access to monoclonal antibody-based products: a global call to action. IAVI. cited Aug 10 2020. Available from: https://www.iavi.org/phocadownload/expanding/Expanding%20access%20to%20monoclonal%20antibody-based%20products.pdf
- Morin S, Segafredo G, Piccolis M. et al. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities. Lancet Glob Health. 2023 Jan Epub 2022 Nov 28;11(1):e145–e154. doi: 10.1016/S2214-109X(22)00460-0
- Global Medicines use in 2020. IQVIA. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-medicines-use-in-2020
- Pricing of biosimilars. GaBi Generics and Biosimilars Initiative. 2012 Mar 23. Available from: https://gabionline.net/biosimilars/research/Pricing-of-biosimilars
- Chowdhury A, Barbera A, Carr S Biosimilar competition: an economist’s perspective. The guide to life sciences – first edition . Oxera Consulting LLP. Oct 21 2022. Available from: https://globalcompetitionreview.com/guide/guide-life-sciences/first-edition/article/biosimilar-competition-economists-perspective
- Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013 Sep;6(8):469–478.
- Biosimilar medicines: overview. European medicines Agency. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview
- Barbier L, Simoens S, Vulto AG, et al. European stakeholder learnings regarding biosimilars: part II-Improving biosimilar use in clinical practice. BioDrugs. 2020 Dec;34(6):797–808. PMID: 33063267; PMCID: PMC7669768. doi: 10.1007/s40259-020-00440-z
- Biosimilar and interchangeable biologics: more treatment choices. FDA. 2021 Dec 10. Available from: https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices
- Kang NH, Wadhwa M, Knezevic I, et al. WHO guidelines on biosimilars: toward improved access to safe and effective products. Annals Of The New York Acad Of Sci. 2023 Mar;1521(1):96–103. doi: 10.1111/nyas.14965
- Kang HN, Thorpe R, Knezevic I, et al. Regulatory challenges with biosimilars: an update from 20 countries. Ann NY Acad Sci. 2021 May;1491(1):42–59. doi: 10.1111/nyas.14522
- Klein K, Gencoglu M, Heisterberg J, et al. The global Landscape of manufacturers of follow-on biologics: an overview of five major biosimilar markets and 15 countries. BioDrugs. 2023 Mar;37(2):235–245. Epub 2022 Dec 6. PMID: 36472773; PMCID: PMC9971138. doi: 10.1007/s40259-022-00568-0
- Boni, S. Pan American Health Organization. Requirements for medicines registration in the Americas . In: Registration WGoM, ed. Pan American network on drug regulatory harmonization series - technical document. (WA) DC: World Health Organization; 2013. p. 1–2.
- Regulatory capacity for biologics in low- and middle income countries. International Federation Of Pharmaceutical Manufacturers & Associations. 2023 Jan. Available from: https://www.ifpma.org/wp-content/uploads/2023/01/i2023_factsheet7.pdf
- Chen Y, Lehmann A, Santos da Silva J What’s next for biosimilars in emerging markets? McKinsey & company. cited Apr 1 2019. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/whats-next-for-biosimilars-in-emerging-markets
- ATOM coalition target countries. Access to oncology medicines coalition. Available from: https://www.uicc.org/atom/focus-areas
- Abraham I Biosimilars and the commoditization of treatments. Center For Biosimilars 2022 (Column). Available from: https://www.centerforbiosimilars.com/view/dr-ivo-abraham-column-biosimilars-and-the-commoditization-of-treatments
- Abraham I 1 billion people can access biosimilars; what about the other 7 billion? Center for biosimilars 2022 (column). Available from: https://www.centerforbiosimilars.com/view/dr-ivo-abraham-column-1-billion-people-can-access-biosimilars-what-about-the-other-7-billion-
- Gavi’s impact: 2000-2021. Gave the vaccine alliance. Available from: https://www.gavi.org/sites/default/files/programmes-impact/our-impact/Gavi-by-the-numbers.pdf